Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

ENMD-2076 in this difficult to treat patient population.  We look forward to working closely with EntreMed and colleagues from other sites in this Phase 2 trial."

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "We are very pleased to have Dr. Oza lead this trial.  Dr. Oza was a principal investigator in our Phase 2 study in platinum resistant ovarian cancer and has been instrumental in advancing our development program targeting this indication.  The cumulative evidence has indicated the potential effectiveness of a combined anti-angiogenic and anti-Aurora A targeted approach in OCCC, and we believe ENMD-2076 presents strong clinical and scientific rationale for the treatment of this subset of patient population.  This trial will provide us with more insight into the drug's clinical activities and its correlation with biomarkers."

Dr. Ren further commented, "Together with our trials in triple negative breast cancer and soft tissue sarcoma, this is the third clinical trial we have initiated for ENMD-2076 under our US/China development model.  We intend to expand the trial into China once we have it underway in Canada and the US.  Our goal is to reach a clinical inflection point using a cost-effective approach that combines speed, quality and lower costs, in order to maximize the value proposition of ENMD-2076. We are confident that we will reach this goal."

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... May 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ... nine months ended March 31, 2012 during the morning of ... a conference call for investors later that day at 3:30 ... nine month periods.  Those interested in participating should call (800) ...
... N.C., May 11, 2012  To broaden their marketing ... strategies and tactics to engage key customer groups ... key opinion leaders. But as they shift to ... viral marketing and other approaches, marketing groups are ...
Cached Medicine Technology:New Report Outlines Use of Innovative Marketing to Engage Customer Groups that are Key to the Pharmaceutical Industry 2
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... NEW YORK April 17, 2014 EcoHealth Alliance, ... public health issues, published a comprehensive review today examining ... and Marburg virus. The review calls for improved global ... such as the recent outbreak of Ebola in West ... in the countries of Guinea and Liberia. According ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today announced ... & Co., a leading global investment bank, as ... evaluating and pursuing alternative,strategies to maximize shareholder value., ... assignment because of its,experience in strategic transactions and ...
... Recent developments regarding,North Carolina,s organ and tissue ... Donation to hire Corder Philips to aid in ... These developments include a grant received from the ... to update their online,registry and increase outreach efforts ...
... Deployed Service Members ... ... the,Military Child Education Coalition,s Supporting the Children of the,National Guard and Reserve ... the Minuteman Emergency,Assistance Fund. The contribution will help support the needs of ...
... VANCOUVER and DEERFIELD, IL, Dec. 11 /PRNewswire-FirstCall/ - ... its co-development partner,Astellas Pharma US, Inc. ("Astellas") today ... of the U.S. Food and Drug,Administration (FDA) has ... of vernakalant hydrochloride, an investigational,new drug for rapid ...
... regions activated by beliefs and human feelings, study shows ... disbelief and uncertainty activate distinct areas of the brain, ... online in the Annals of Neurology . ... was monitored using functional magnetci resonance imaging (fMRI) while ...
... genome-wide association studies have identified a genetic variant ... the risk of aggressive prostate cancer. Research teams ... Forest University School of Medicine, the Karolinska Institute ... made the discovery jointly. , Researchers suspect that ...
Cached Medicine News:Health News:QLT Appoints Goldman, Sachs & Co. as financial advisor in review of strategic options to enhance shareholder value 2Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:TriWest Contributes $25,000 to Washington National Guard Fund and Sponsors Education for Teachers of Military Children 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 3Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 4Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 5Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 6Health News:Personal Convictions May Control Both Behavior and Emotions 2Health News:Study finds gene linked to aggressive prostate cancer 2Health News:Study finds gene linked to aggressive prostate cancer 3
... long, thick-walled cannula which contains a coaxial ... Helical Loop Basket and a Tip Deflecting ... the outer cannula to carry these two ... right atrium. (Requires a Handle for Tip ...
... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... The cost-effective, proven and reliable system. ... for rapid patient treatment, fastest beam-on ... - less than 500 milliseconds, pulse-to-pulse ... beam stability, greatest number of multileaf ...
Medicine Products: